Glomerular tip lesion: A distinct entity within the minimal change disease/focal segmental glomerulosclerosis spectrum.
The glomerular tip lesion (GTL) is a distinctive histopathologic lesion occurring in patients with idiopathic nephrotic syndrome. As first described by Howie and Brewer in 1984 [1] , GTL is a segmental glomerular lesion defined by its characteristic location at the origin of the proximal tubule and exhibiting both intracapillary and extracapillary alterations. In their elegant studies of renal biopsies using serial sections [1, 2] , these investigators found a small portion of the glomerular tuft situated at the tubular pole to be expanded either by endocapillary foam cells with pale vacuolated cytoplasm or acellular hyaline material, usually accompanied by adhesion between the involved glomerular segment and Bowman's capsule or the tubular basement membrane. In serial sections, these changes involve all or nearly all glomeruli. The overlying podocytes are typically swollen and hyperplastic, containing cytoplasmic vacuoles and protein resorption droplets. Frequently there is confluence of these enlarged visceral epithelial cells with the adjacent proximal tubular epithelial cells, which may appear small and capped or swollen and vacuolated. The remainder of the tuft is histologically normal but shows extensive effacement of foot processes at the ultrastructural level, resembling the podocyte alterations seen in minimal change disease (MCD). By immunofluorescence, there may be segmental positivity for IgM and C3 in the tip region, similar to the immunofluorescence profile seen in focal segmental glomerulosclerosis (FSGS). Because these glomerular changes occur in patients with idiopathic nephrotic syndrome, the relationship of this segmental lesion to MCD and idiopathic FSGS has been a source of controversy.
The natural history of GTL is poorly defined. In repeat biopsies from patients with GTL, Howie and Brewer found persistence of GTL in most patients [1, 2] . However, in some cases the segmental lesions had evolved to affect a larger glomerular area, extending from the apex to the vascular pole and some repeat biopsies contained lesions of segmental and global sclerosis, indicating possible progression to irreversible glomerular scarring [1] . In a subsequent study, Howie et al [3] emphasized that cases where GTL involved all (or nearly all) glomeruli that are otherwise histologically unremarkable were usually steroid-responsive and had long-term preservation of renal function. In contrast, cases of GTL accompanied by diffuse mesangial hypercellularity, cases with diffuse multiple segmental lesions involving all or nearly all glomeruli, and cases of focal GTL involving fewer than 50% of glomeruli per biopsy behaved more like idiopathic FSGS and frequently did not undergo remission. However, progression of GTL to FSGS with development of end-stage renal disease (ESRD) has been documented in some patients including at least one patient with typical GTL on initial biopsy (i.e., diffuse GTL, without mesangial hypercellularity) [2] .
Although first described in biopsies that otherwise resemble MCD [1, 2] , GTL has since been reported in biopsies where segmental lesions were not restricted to the tubular pole [4, 5] , akin to idiopathic FSGS. These conflicting data raise questions about how GTL should be defined within the MCD/FSGS spectrum and whether it constitutes a distinct clinical-pathologic entity or should be considered a morphologic variant of FSGS. "Glomerular tip changes," identical to GTL, may also occur superimposed on diverse glomerular diseases, including membranous nephropathy [6] , diabetic nephropathy [6] , IgA nephropathy [6] , chronic allograft nephropathy [7] , postinfectious glomerulonephritis [8] , and following pre-eclampsia [9] . Similar pathologic findings have also been described in some experimental models of proteinuric renal disease [10, 11] , suggesting that GTL might represent a nonspecific glomerular response to proteinuria. Howie et al [8] have proposed that acute swelling of the glomerular tuft in different glomerular diseases leads to reversible prolapse of the peripheral tuft into the tubular lumen. In proteinuric glomerulopathies, the convergence of protein-rich filtrate toward the tubular pole may cause physical stress on the paratubular glomerular segments, leading to accumulation of endocapillary foam cells, swelling and detachment of podocytes, and subsequent tuft adhesion to Bowman's capsule.
We report the clinical-pathologic features, treatment, and outcome of 47 patients with GTL diagnosed at our institution. Presenting clinical features were compared to those of a cohort of MCD and classic idiopathic FSGS. Our results confirm that GTL falls within the clinicalpathologic spectrum of MCD/idiopathic FSGS, but more closely resembles MCD with respect to presenting features and prognosis. Our data support the view that GTL is a distinct clinical-pathologic entity with prognostic significance.
METHODS
Forty-seven cases of GTL were identified retrospectively from among 10,173 native renal biopsies accessioned in the Renal Pathology Laboratory at Columbia Presbyterian Medical Center between January 1991 and March 2003, for a biopsy incidence of 0.46%. GTL was defined according to the guidelines of a recent consensus classification [12] . Morphologic inclusion criteria were the presence of at least one glomerulus containing a segmental lesion involving the tip domain (i.e., the outer 25% of the glomerular tuft next to the origin of the proximal tubule) with either adhesion between the tuft and Bowman's capsule at the tubular lumen or neck, or confluence of podocytes with parietal or tubular epithelial cells at the tubular lumen or neck (Fig. 1A) . It was required that the proximal tubular pole be identified in the defining glomerulus. The GTL could have cellular features (endocapillary hypercellularity, including foam cells) (Fig. 1B) or sclerosing features (increased matrix and/or hyalinosis) (Fig. 1C) . Exclusion criteria included (1) any glomerulus with collapsing sclerosis and (2) any case with clinical-pathologic features of another primary glomerular disease (such as membranous nephropathy, IgA nephropathy, or diabetic glomerulosclerosis).
Clinical data, laboratory findings at presentation, and follow-up data were obtained from review of biopsy referral forms and from follow-up telephone conversations with the submitting nephrologists. For adults (≥18 years of age), the following clinical definitions were used: nephrotic range proteinuria (NRP), >3 g/day; hypoalbuminemia, serum albumin <3.5 g/dL; hypercholesterolemia, serum cholesterol >200 mg/dL; renal insufficiency, serum creatinine >1.2 mg/dL; hematuria, >5 red blood cells per high power field on microscopic examination of the urinary sediment. Nephrotic syndrome was defined as NRP, hypoalbuminemia, and peripheral edema. Hypertension was defined as systolic blood pressure >140 mm Hg or diastolic blood pressure >90 mm Hg. For the two subjects aged <18 years at initial presentation, NRP was defined as >40 mg/m 2 /hour [13] ; hypoalbuminemia was defined as <2.5 g/dL [13] , renal insufficiency was defined by a calculated creatinine clearance of less than 90 mL/min [14] , and hypertension was defined as a systolic or diastolic blood pressure > the 90th percentile based on the child's gender, age, and height percentile [15] . An estimate of glomerular filtration rate (GFR) was calculated using a modified Cockcroft-Gault formula corrected for gender, age, and serum creatinine. For outcome analysis, stable renal function was defined as a change in serum creatinine of ≤20% of the initial value. Complete remission was defined as 24-hour urine protein of ≤300 mg/day (or dipstick trace) and stable renal function at last follow-up. Partial remission was defined by the presence of a 24-hour urine protein of ≤2 g/day (or up to 2+ by dipstick), a reduction in proteinuria of at least , and stable renal function at last follow-up. ESRD was defined as the time point when renal replacement therapy was started. For purposes of comparison, the presenting demographic and clinical features of the GTL group were compared to those of a control group of 61 consecutive adult MCD cases (all >18 years old) diagnosed between 1998 and 2003, and a well-characterized historical control group of 50 patients with classic idiopathic FSGS biopsied at our institution [16] .
Renal biopsies were processed for light microscopy (LM), immunofluorescence (IF), and electron microscopy (EM) according to standard techniques. For LM, at least 11 glass slides, each containing two to three tissue sections (3 lm thick), were stained with hematoxylin and eosin, periodic acid-Schiff (PAS), Masson's trichrome, and Jones methenamine-silver (JMS) stains. Routine IF was performed on 3 lm thick cryostat sections using polyclonal fluorescein isothiocyanate (FITC)-conjugated antibodies to IgG, IgM, IgA, C3, C1q, j, k, fibrinogen, and albumin (Dako Corporation, Carpenteria, CA, USA). EM was performed using a JEOL 100S electron microscope.
The percentage of globally sclerotic glomeruli and segmental lesions in each biopsy was calculated. Each segmental lesion was categorized based on its location with respect to the tubular pole and glomerular hilus as either (1) GTL, a segmental lesion involving the tip domain (i.e., the peripheral 25% of the glomerular tuft adjacent to the origin of the proximal tubule, with either adhesion between the tuft and Bowman's capsule at the tubular lumen or neck, or confluence of podocytes with parietal or tubular epithelial cells at the tubular lumen or neck) (Fig. 1A) ; (2) peripheral lesion, a segmental lesion that was either adjacent to the tubular pole, or distant from the hilar arteriole, but that did not form a GTL in adjacent serial sections; (3) perihilar lesion, a segmental lesion involving the glomerular vascular pole; or (4) indeterminate lesions, a segmental lesion whose relationship to the vascular pole or the origin of the proximal tubule could not be determined due to the plane of sectioning. For proper assignment of each segmental lesion to one of the above categories, all serial sections of the biopsy were carefully reexamined and each segmental lesion was tracked through the serial sections for identification of the vascular and tubular pole. Next, each segmental lesion was subclassified as either (1) cellular (with endocapillary hypercellularity, including foam cells) (Fig. 1B) or (2) sclerosing (with increased matrix and/or hyalinosis) (Fig. 1C) . Podocyte hypertrophy and/or hyperplasia were permissible in both the cellular and sclerosing lesions. Mesangial hypercellularity, defined by >3 cells/mesangial region, was graded semiquantitatively on a scale of 0 to 3+ corresponding to absent, mild, moderate, and severe.
Acute tubular injury was identified by the presence of tubular simplification, loss of brush border, and enlarged reparative nuclei with nucleoli. Tubular atrophy, interstitial fibrosis, interstitial edema, interstitial inflammation, and acute tubular injury were graded semiquantitatively on a scale of 0 to 3+ based on the % cortical area affected (<1%, 1% to 25%; 26% to 50%; and >50%, respectively). Arteriosclerosis and arteriolosclerosis were graded 0 to 3+ (absent, mild, moderate, and severe, respectively) based on the degree of luminal narrowing and vessel wall thickening. The intensity of IF staining was graded 0 (absent), trace (+/−), or 1 to 3+. The percentage of foot process effacement was determined quantitatively by estimation (without using morphometric measurements) based on examination of the ultrastructure of all nonsclerotic glomerular capillaries in all fields studied.
Statistical analysis
Statistical analysis was performed using nonparametric exact statistical methods, including the Fisher exact test (for categorical variables), the Wilcoxon rank sum test (for continuous variables between two groups), the Kruskal-Wallis test and the Jonckheere-Terpstra test (for continuous variables among three or more groups), 
RESULTS

Demographic and presenting clinical features of GTL
The cohort of GTL patients included 25 males and 22 females ( Table 1 ). The mean age at presentation was 47.5 years (range 12 to 79 years), including 45 adults and two children, aged 12 and 15 respectively. There were 36 Caucasian patients (76.6%), six African Americans (12.8%), four Hispanics (8.5%), and one Asian (2.1%).
Presenting laboratory data were available for 46 GTL patients, all of whom had heavy proteinuria (Table 1) . In the single remaining patient, detailed clinical data were not available, although the patient was described as having nephrotic syndrome. The mean 24-hour urinary protein measured in 44 patients was 8.31 g, (range 2.4 to 19.8 g), including 41 with proteinuria >3g/day and three with subnephrotic proteinuria (mean 2.6 g/24 hours, range 2.4 to 2.9 g/24 hours). Two additional subjects had 4+ dipstick proteinuria, peripheral edema, and hypoalbuminemia (1.5 g/dL and 2.2 g/dL, respectively), consistent with probable nephrotic syndrome. Forty-three patients had edema that, in most cases, was described by the referring nephrologist as abrupt in onset. Serum albumin data were available for 43 patients (mean serum albumin 2.27 g/dL, range 1.3 to 3.8 g/dL), of whom 42 (97.7%) had hypoalbuminemia. The single exception was an individual who had a serum albumin level of 3.8 g/dL and presented with sudden onset edema with a urinary protein excretion of 3.4 g/24 hours. Overall, 41/46 patients (89.1%) fulfilled the three defining criteria for nephrotic syndrome, and four others had two of the three criteria. The mean duration of renal symptoms prior to biopsy was 2.4 months (median 1 month, range 0.5 to 12 months). Among 32 patients with available data, 29 (90.6%) had hypercholesterolemia at presentation with a mean serum cholesterol of 340.6 mg/dL (range 132 to 778 mg/dL). Twenty-three of 40 patients (57.5%) had microhematuria but none had red blood cell casts. Twenty-eight of 46 subjects (61%) had hypertension that was longstanding in 26 and newly diagnosed in two. At presentation, 30/46 patients (65.2%) had normal renal function (mean serum creatinine 0.95 mg/dL, range 0.5 to 1.2 mg/dL) and 16/46 patients (34.8%) had renal insufficiency (mean creatinine 2.14 mg/dL, range 1.3 to 5.2 mg/dL). The latter group included eight patients who had recently documented normal renal function and one subject who had longstanding mild proteinuria and chronic renal insufficiency. Previous renal function in the other seven patients was unknown. Thus, at least 8/46 GTL patients (17.4%) had new onset renal insufficiency at presentation.
Clinical and serologic findings in GTL patients not detailed in Table 1 included five with low titer positive antinuclear antibody but with no other clinical or laboratory evidence of systemic lupus erythematosus (SLE); two with monoclonal spike on serum electrophoresis, but without clinical or radiological evidence of multiple myeloma; one with human immunodeficiency virus (HIV) infection; one with positive hepatitis B surface antigen and positive hepatitis C virus antibody; one with low titer antineutrophil cytoplasmic antibody (ANCA); one with anticardiolipin antibody; one with type 2 cryoglobulinemia; and one with sarcoidosis. Of note, the one individual with HIV infection was a Caucasian male whose biopsy did not reveal evidence of HIV nephropathy (i.e., collapsing FSGS, tubular microcysts, or endothelial tubuloreticular inclusions). One subject had lymphoma treated with chemotherapy 9 years prior and was undergoing treatment with corticosteroids for Waldenstrom's macroglobulinemia at the time of renal biopsy. Detailed clinical information regarding recent nonsteroidal anti-inflammatory drug use was not available in most cases, but in no instance was there a strong suspicion of drug-related glomerular disease at the time of renal biopsy.
Pathologic findings
The renal biopsy findings in GTL are presented in Table 2 . By LM, the total number of glomeruli examined in each biopsy ranged from 6 to 100 (mean 25.1, median 20) and the percentage of globally sclerotic glomeruli ranged from 0% to 45% (mean 7%, median 1.8%). The percentage of segmental lesions per biopsy ranged from Most segmental glomerular lesions in the cohort of GTL were cellular (average 81% of lesions per biopsy) and a minority was sclerosing (average 19% of lesions per biopsy) ( Table 2) . Among the entire cohort of 47 GTL biopsies, 33 (70.2%) had cellular lesions only, five (10.6%) had sclerosing lesions only, and nine (19.1%) had both cellular and sclerosing lesions. Of the 12 biopsies showing exclusively GTL, nine (75%) had cellular lesions only, two (16.7%) had sclerosing lesions only, and one case (8.3%) showed both cellular and sclerosing lesions. On average, 81% of glomerular lesions in this group were cellular and 19% were sclerosing ( Table 2 ). All three biopsies with GTL and peripheral lesions showed only cellular lesions. Of the 17 biopsies with both GTL and indeterminate lesions, 12 (70.6%) had cellular lesions only, three (17.6%) had sclerosing lesions only, and two (11.8%) had both cellular and sclerosing lesions. On average, 73% of segmental lesions per biopsy in this group were cellular and 27% were sclerosing. Of the 15 biopsies with GTL, peripheral and indeterminate lesions, 11 (73%) had cellular lesions only, one (7%) had sclerosing lesions only, and three (20%) showed both cellular and sclerosing lesions. On average, 85% of segmental lesions in this group were cellular and 15% were sclerosing. Twenty-two biopsies showed mild focal mesangial hypercellularity (mean score 0.5; scale 0 to 3+) and no biopsy demonstrated diffuse mesangial hypercellularity.
Most GTL biopsies showed either no or mild interstitial fibrosis and tubular atrophy (mean score 0.7+; scale 0 to 3+). Fourteen biopsies had patchy interstitial edema and a mild interstitial mononuclear inflammatory cell infiltrate, without significant interstitial fibrosis. Acute tubular injury was identified in 14 biopsies (mean score 1.9+, range 1 to 3+). Proximal tubular epithelial cells frequently contained focal intracytoplasmic protein resorption droplets. Arteriosclerosis was generally mild (mean score 0.7+; scale 0 to 3+).
IF demonstrated focal and segmental glomerular staining for IgM (in 77.7% of biopsies) and for C3 (in 43.2% of biopsies). The mean intensity (MI) of staining for IgM was 0.8 ± 0.1 (scale 0 to 3+) and, for C3, 0.6 ± 0.1. No biopsy showed diffuse mesangial IgM staining, or the predominant C1 staining characteristic of C1q nephropathy (MI for C1q 0.14 ± 0.05). No biopsy had glomerular staining for IgG or IgA. EM demonstrated extensive foot process effacement (mean 93.5%, range 50% to 100%) ( Fig. 2A) . There was no evidence of underlying structural glomerular basement membrane abnormalities, immunetype electron-dense deposits or endothelial tubuloreticular inclusions, including the one patient with HIV infection. The tip lesions often displayed endocapillary foam cells and swelling of the overlying podocytes (Fig. 2B) .
Clinical follow-up
Follow-up renal data were obtained in 29 patients and the mean follow-up period was 21.6 months (range 3 to 96 months) ( Table 3 ). There were no statistically significant differences in presenting clinical features or biopsy findings between those patients with vs. without followup. All 29 patients received immunosuppressive therapy, including steroids in 28. Seven of these patients had sequential treatment with steroids followed by another immunosuppressive agent, including cyclosporine (CSA) alone (N = 3), CSA + intravenous cytoxan (N = 2), or intravenous cytoxan alone (N = 2). One patient was treated with CSA alone. Twenty-two patients, all of whom received steroids, also received an angiotensinconverting enzyme (ACE) inhibitor or angiotensin II receptor blocker (ARB). Seventeen patients (58.6%) achieved complete remission defined as trace or no proteinuria (<300 mg/day) and normal renal function at last follow-up (mean 15.5 months, range 3 to 30 months). All 17 patients with complete remission had received steroid therapy, including 13 treated with prednisone alone; three who also received CSA; and one who also received IV cytoxan followed by CSA. Thirteen of the 17 patients also received an ACE or ARB. The mean initial serum creatinine in complete remission patients was 1.15 mg/dL (range 0.5 to 2.7 mg/dL) and the mean final serum creatinine was 1.05 mg/dL (range 0.7 to 2.5mg/dL). The mean 24-hour urinary protein excretion decreased from 7.8 ± 1.05g (initial) to negative/dipstick trace at last follow-up.
Four patients (13.8%) had partial remission defined as nonnephrotic proteinuria (<2 g/day) and stable renal function at last follow-up (at 3, 13, 18, and 48 months, respectively). All four partial remission patients received steroids + ACE or ARB. One patient underwent complete remission following 6 months of steroid therapy but nephrotic syndrome relapsed 6 months later and was partially controlled with CSA at last follow-up. One partial remission subject, treated with steroids + ACE, had persistent 2+ dipstick protein when he suffered an unnatural death 3 months after initial presentation. One partial remission patient with steroid-resistant nephrotic syndrome showed marked diminution of proteinuria (to 1 g/24 hours) with CSA + ACE/ARB; 3 years later, nephrotic syndrome relapsed and was partially controlled (1 g/24 hours) with cytoxan + ACE + ARB at last follow-up. In one partial remission individual, steroid therapy was discontinued after 3 months because of uncontrolled hyperglycemia; this patient had persistent, albeit markedly reduced proteinuria (from 12 to 1 g/day) on ACE alone 18 months later. The mean initial serum creatinine in partial remission patients was 1.15 mg/dL (range 0.6 to 1.6 mg/dL) and the mean final serum creatinine was 1.18 mg/dL (range 1 to 1.4 mg/dL). The mean initial 24-hour urinary protein excretion in partial remission patients was 10.4 ± 3.17 g and the mean final 24-hour urinary protein excretion was 1.0 ± 0.0 g.
Eight patients (27.6%) were classified as nonremitters because of persistent and significant proteinuria (dipstick 2+ or >2 g/day) at last follow-up (mean 27.9 ± 11.9 months, range 4 to 96 months). Treatment regimens in these eight subjects consisted of: prednisone alone (one patient); prednisone + ACE/ARB (three patients); prednisone + CSA + ACE/ARB (one patient); prednisone + cytoxan (one patient); prednisone + cytoxan + ACE/ARB (one patient); and CSA + ACE/ARB (one patient). Steroid therapy was avoided in one patient because of morbid obesity, and poor compliance with medication was suspected in one other patient. Of note, three of these patients, all of whom received steroids + ACE/ARB, demonstrated marked reductions in proteinuria at last follow-up (from 19.8 to 4.9 g, from 12.5 to 6 g, and from 12 to 3 g, respectively) but did not fulfill the criteria for remission of nephrotic syndrome. The mean initial 24-hour urinary protein excretion in nonremitting patients was 11.7 ± 1.91 g and the mean final 24-hour urinary protein excretion was 6.82 ± 1.57 g. The mean initial serum creatinine in the eight nonremitting patients was 1.3 mg/dL (range 0.8 to 2.2 mg/dL). At last follow-up, five nonremitting patients had a mean serum creatinine of 1.3 mg/dL (range 0.9 to 2.1 mg/dL) and one had a creatinine clearance of 78 mL/min. Renal functional data were unavailable for one individual. The single patient treated with steroids alone progressed to ESRD after 36 months' follow-up.
Of the 16 patients who had renal insufficiency at presentation, three had normal renal function at last followup (mean initial serum creatinine 1.6 ± 0.21 mg/dL, mean final serum creatinine 0.9 ± 0.1 mg/dL), eight were lost to follow-up, and the remaining five had persistent but stable renal impairment (mean initial serum creatinine 2.0 ± 0.22 mg/dL, mean final serum creatinine 1.8 ± 0.3 mg/ dL).
Relapse of nephrotic syndrome after initial response to immunosuppressive therapy was documented in two patients (at 6 months post-therapy and 43 months posttherapy, respectively); both patients were classified as partial remitters at last follow-up. Of the 18 patients for whom follow-up renal data were not obtained, one patient died of sepsis while receiving steroids 1 month postrenal biopsy; one, who had received steroids, died of a myocardial infarction 6 months postrenal biopsy; three patients had follow-up of less than 2 months; and 13 were lost to follow-up.
Repeat renal biopsies in GTL
Three GTL patients underwent repeat renal biopsy because of failure to remit following steroid therapy, including the single patient who progressed to ESRD. This patient was a 29-year-old woman who presented with nephrotic syndrome and normal renal function. Initial renal biopsy demonstrated cellular segmental lesions in 8/22 glomeruli (36.4%), including five cellular GTL, one cellular peripheral lesion, and two cellular indeterminate lesions (Fig. 1F and G) . There was no evidence of segmental sclerosing lesions, global glomerulosclerosis, interstitial fibrosis, tubular atrophy, or arteriosclerosis. She underwent repeat renal biopsy 3 years later because of steroid-resistant nephrotic syndrome and progressive renal failure. The second biopsy showed global glomerulosclerosis affecting four of eight glomeruli (50%) and segmental sclerosis and hyalinosis in two glomeruli (25%). The segmental lesions involved most of the glomerular tuft, including the hilar pole, and were accompanied by severe interstitial fibrosis and tubular atrophy and moderate arteriosclerosis (Fig. 1H) .
A second patient showed segmental lesions in 3/19 glomeruli (15.6%) in the first biopsy, (including one cellular GTL, one cellular peripheral lesion, and one cellular indeterminate lesion) without features of global glomerulosclerosis, interstitial fibrosis and tubular atrophy, or arteriosclerosis. This patient's second biopsy (performed 30 months later because of failure to respond to immunosuppressive therapy) showed global glomerulosclerosis in 5/27 glomeruli (18.5%) and segmental sclerosing lesions in 3/27 glomeruli (11.1%), including one sclerosing GTL and two sclerosing lesions of indeterminate location. These findings were accompanied by severe interstitial fibrosis and tubular atrophy and moderate arteriosclerosis. This patient had persistent NRP at last follow-up.
A third individual showed mild global glomerulosclerosis (1/6 glomeruli, 16.7%) and cellular GTL (1/6 glomeruli, 16.7%) in the first biopsy, accompanied by mild arteriosclerosis. A repeat biopsy performed 2 months later because of nonresponse to steroid therapy contained five glomeruli, three of which showed segmental lesions including one cellular GTL, one cellular peripheral lesion, and one segmental sclerosing lesion of indeterminate location. At last follow-up (19 months), this patient was in complete remission and had normal renal function.
Clinical-pathologic correlations in GTL
Correlations between pathologic and clinical findings, including renal status at last follow-up, are summarized in Table 4 . Renal insufficiency at presentation correlated with older age (P = 0.007), male gender (P = 0.002), percentage of peripheral lesions (P = 0.014), and higher final serum creatinine (P = 0.012), but not with duration of symptoms prior to biopsy (data not shown). Five of the 16 patients presenting with renal insufficiency showed prominent diffuse acute tubular injury (mean score 2.4+, range 2 to 3+); two of these patients had normal renal function at last follow-up, similar to previously described findings in MCD patients presenting with reversible acute renal failure [17] . The other 11 cases showed mild or moderate acute tubular injury (mean score 1.4, range 1 to 2). Of note, the eight nonremitters presented with significantly higher initial urinary protein excretion compared to the 21 patients who had either partial (N = 4) or complete remission (N = 17) (P = 0.030).
The degree of proteinuria correlated with interstitial inflammation score (P = 0.045) and with interstitial edema score (P = 0.029). In univariate analyses, the extent of tubular atrophy and interstitial fibrosis correlated with % global glomerulosclerosis (P = 0.001), % sclerosing GTL (P < 0.001), and % segmental sclerosing lesions (all locations) (P < 0.001). Nonparametric univariate analyses showed that the estimated GFR at presentation correlated with: % global glomerulosclerosis (R = −.0.321, P = 0.030); % peripheral lesions (sclerosing) (R = −0.317, P = 0.032); and % peripheral lesions (cellular + sclerosing) (R = −0.306, P = 0.032). By Data are mean ± SEM, except where otherwise indicated. a P < 0.001, idiopathic FSGS versus GTL and versus MCD; b P < 0.05, MCD versus GTL and versus idiopathic FSGS; c P < 0.05 MCD versus idiopathic FSGS; d P < 0.001, idiopathic FSGS versus GTL and versus MCD; e In MCD, "new onset" assumed at 1 month for purposes of analysis.
multiple (multivariate) linear regression analysis, only % global glomerulosclerosis (P = 0.006) and % peripheral lesions (P = 0.021) correlated with estimated GFR at presentation (combined Spearmann R value 0.471, overall P = 0.005).
There was no significant difference in final remission status (complete remisson versus partial remission versus no remission) when cases with GTL alone (N = 12) were compared to cases of GTL with lesions at other glomerular locations (N = 35) (P = 0.8795, Kruskal Wallis test). However, compared to patients with GTL alone, patients with GTL + any other lesion (peripheral and/or indeterminate) had significantly higher final urinary protein excretion (P = 0.045) ( Table 5 ). The percentage of peripheral lesions (non-GTL) correlated significantly with higher initial serum creatinine (P = 0.037), estimated GFR at presentation (P = 0.032), renal insufficiency at presentation (P = 0.014), and the absence of remission at last follow-up (P = 0.020) ( Table 4) . No significant correlations were identified between final remission status and % GTL, % indeterminate lesions, % sclerosing lesions, interstitial fibrosis/tubular atrophy score, mesangial proliferation score, or arteriosclerosis score. The development of ESRD in only one GTL patient precluded the identification of clinical or pathologic features that might predict progression.
Comparison of GTL to MCD and idiopathic FSGS
As shown in Table 6 , gender and racial/ethnic distribution did not differ significantly between patients with GTL, MCD, and idiopathic FSGS. However, GTL and MCD patients were significantly older than patients with idiopathic FSGS (P < 0.001). Although the clinical presenting features of GTL demonstrated considerable overlap with those of MCD and idiopathic FSGS, the greatest similarity with respect to nephrotic parameters was found between the GTL and MCD groups. In GTL and MCD, 89.1% and 96.7% of patients respectively presented with full nephrotic syndrome compared to only 54% of patients with idiopathic FSGS (P < 0.001). Notably, both GTL and MCD patients tended to present with abrupt onset of nephrotic syndrome, as reflected by the significantly shorter intervals from onset of symptoms to biopsy compared to idiopathic FSGS (P < 0.001). The incidence of hypertension at presentation was similar in GTL (59%) and idiopathic FSGS (56%), and significantly higher than in MCD (37.5%) (MCD vs. GTL and idiopathic FSGS, each P < 0.05). There was no statistically significant difference in serum creatinine between the three groups, reflecting the well-recognized occurrence of acute renal failure in a subset of adults with MCD. Idiopathic FSGS biopsies showed significantly more severe (2+ or greater) tubular atrophy, interstitial fibrosis, and interstitial inflammation (P < 0.0054). The extent of foot process effacement in GTL cases (mean 93.5% of glomerular capillary surface area) was more similar to that of MCD (mean 91.6%) than idiopathic FSGS (mean 75%).
DISCUSSION
Pure GTL has been reported in 4.9% to 13.5% of FSGS biopsy series [1, 4, 5] . In the first description of 20 patients with GTL, this lesion comprised 13.5% of biopsies initially classified as FSGS [1] . GTL also may coexist with other lesions of FSGS, in either perihilar, peripheral, or indeterminate locations. In a study of 44 nephrotic children with FSGS, including 33 with repeat biopsies or autopsies, Morita et al [5] classified the locations of segmental lesions as either GTL ("paratubular"), peripheral, hilar (i.e., perihilar), or indeterminate. GTL was found in 23 initial biopsies (52.3%) but 19 of these cases (82.6%) showed hilar sclerosis in either the initial or repeat biopsies, similar to idiopathic FSGS. Only four cases (9.1%) were classified as pure GTL, based on the absence of hilar or indeterminate sclerosing lesions in the initial or repeat biopsies, or at autopsy [5] . Similarly, Schwartz et al [4] described GTL in 26% of 81 FSGS biopsies but tip lesion was the sole finding in only four cases (4.9%). In neither of these studies was there a statistically significant difference in outcome for the peripheral or GTL groups compared to the hilar sclerosis patients, perhaps reflecting the small number of pure peripheral or GTL cases examined. We did not identify perihilar sclerosis in any of our 47 initial biopsies of GTL, supporting that GTL is morphologically distinct. However, the development of perihilar sclerosis on repeat biopsy in one of our cases indicates that rare cases may evolve into a pattern of idiopathic FSGS not otherwise specified [12] .
Howie and Brewer [1] have demonstrated that the frequency of GTL lesions is directly related to the number of tissue sections examined, with most glomeruli involved when 100 sections were examined, whereas the fraction of glomeruli with GTL in each biopsy ranged from 3% to 16% when only one-tenth of available sections were studied. However, given the random orientation of the spherical glomerulus within the tissue block, it follows that some GTL may not always be visualized, even after exhaustive sectioning. Precise determination of the frequency of GTL properly requires the use of stereologic methodologies that are not practicable in routine renal biopsy practice, and, moreover, cannot be applied retrospectively in a clinical-pathologic study of the present kind. Of note, using conventional histologic techniques, Haas and Yousefzadeh [18] identified GTL in five of eight (62.5%) pediatric autopsy specimens with "lipoid nephrosis" from the archives of Johns Hopkins Hospital, but only 0.3% to 4.4% of glomeruli had GTL, despite examination of 410 to 1168 glomeruli per case. Similarly, using standard biopsy examination techniques, we found that GTL is always a focal histologic finding, with no case demonstrating >50% glomerular involvement.
Howie [3] proposed a classification of segmental glomerular lesions based on the extent of glomerular involvement in addition to the location of individual lesions within the glomerular tuft. In that study, cases with GTL involving all or nearly all glomeruli that otherwise resembled MCD (i.e., did not show mesangial proliferation or sclerosing lesions at other sites) had a uniformly benign course with complete remission occurring in all 10 cases. Cases of diffuse GTL with mesangial hypercellularity, cases with diffuse multiple segmental lesions at various parts of the glomerular tuft involving all or nearly all glomeruli, and cases with focal GTL (i.e., fewer than 50% of glomeruli affected) behaved more like idiopathic FSGS, with failure to enter remission in many cases [3] . Our findings, on the other hand, indicate that focal lesions are the rule in cases of GTL when renal biopsies are examined by conventional techniques. None of our cases showed diffuse mesangial hypercellularity, and the presence of mild segmental mesangial hypercellularity in a minority of cases did not have any significant impact on clinical presenting features, response to therapy, or long-term renal outcome. Importantly, perihilar segmental lesions were not identified in any initial biopsy in this series; only one case that progressed to ESRD showed hilar lesions on repeat biopsy. Thus, while perihilar lesions were not an exclusion criterion for case selection, the discovery that they were absent in all initial GTL biopsies provides post hoc evidence to support a classification system that requires exclusion of any perihilar sclerosis in its definition of GTL [12] .
In this study, we demonstrate that GTL frequently coexists with other lesions whose relationship to the proximal tubule is uncertain (peripheral and/or indeterminate). This raises the important question of whether GTL cases with peripheral and/or indeterminate segmental lesions are distinct from cases with GTL alone and should be classified separately as FSGS not otherwise specified. The presence of peripheral lesions correlated with renal insufficiency at presentation, higher final urinary protein and absence of complete remission at last followup. Thus, cases that showed peripheral lesions (GTL + peripheral, or GTL + peripheral + indeterminate) had significantly worse renal outcomes compared to cases of GTL alone or GTL + indeterminate. On the other hand, when we dichotomized cases of GTL alone versus cases of GTL + any other lesion, there was no difference in final remission status between the two groups, which supports the concept that these subgroups constitute a single clinical-pathologic entity. In reviewing all GTL cases, we frequently encountered apparently peripheral and/or indeterminate segmental lesions that could be classified as GTL when tracked through adjacent tissue sections. Thus, we cannot exclude the possibility some peripheral and/or indeterminate lesions are GTL whose relationship to the tubular pole is not visualized in the sections examined or that evolved beyond the tip domain. Given the constraints of routine tissue processing, and the inability to precisely distinguish GTL, peripheral, and indeterminate lesions without resort to exhaustive tissue sectioning, we believe it is justifiable to include cases of GTL with peripheral and/or indeterminate lesions within the diagnostic category of GTL, while noting that the presence of peripheral lesions in GTL may portend a worse clinical outcome, more akin to idiopathic FSGS not otherwise specified.
The prognostic import of sclerosing versus cellular GTL has not been examined before. Most of the focal lesions in this study were cellular in type. The findings of sclerosing GTL in repeat biopsies from three individuals whose initial biopsies all showed only cellular lesions is consistent with the hypothesis advanced by Howie and Brewer [1] that cellular GTL may evolve into sclerosing GTL. Of note, one of these three patients progressed to ESRD, one had persistent nephrotic proteinuria, and one subsequently entered complete remission. However, the % segmental sclerosing lesions in the initial biopsy did not correlate with estimated GFR at presentation, or with follow-up renal functional data, suggesting that the presence of sclerosing versus cellular segmental lesions in GTL does not carry major prognostic import.
In the initial study of Howie and Brewer of GTL [1] , all sixteen patients who were treated with steroids showed decreased proteinuria and only one untreated patient developed progressive renal impairment, suggesting a favorable prognosis. Hogan-Moulton et al described a similar high rate of steroid responsiveness in GTL, with progression to ESRD occurring in only 1 of 28 patients [abstract A418; Hogan-Moulton AE et al, J Am Soc Nephrol 8:87A, 1997]. Beaman et al [20] reported remission of nephrotic proteinuria in 10 of 18 patients with GTL following steroid treatment, and partial remission of proteinuria in seven. Similarly, Ito et al [21] reported significantly better clinical outcomes in children with idiopathic nephrotic syndrome whose biopsies showed peripheral segmental lesions compared to perihilar lesions. Although not described in detail, it is probable that at least some of the peripheral lesions in that study included cases of GTL. In the studies of Schwartz et al [4] and Morita et al [5] , three of four patients with initial biopsy findings of pure GTL had complete remission and stable renal function, and one had normal renal function and minimal proteinuria following steroid therapy. Other groups, on the other hand, reported no prognostic significance for "tip changes" [4, 5] or peripheral lesions [22, 23] compared to idiopathic FSGS. Whether this discrepancy reflects the possible inclusion of other primary glomerular diseases beside GTL [24] [25] [26] or the small number of GTL cases in some series [4, 5] is uncertain. Our study, which is the largest single-center series of GTL yet reported, confirms the high likelihood of response to immunosuppressive therapy in GTL, with complete or partial remissions occurring in 72.4% of patients.
Our data strongly support the hypothesis that GTL falls within the MCD/FSGS disease spectrum. The high incidence of full nephrotic syndrome and abrupt clinical onset seen in GTL resemble the presentation of MCD. The remission rate of 72.4% of GTL (58.6% complete and 13.8% partial) is intermediate between published remission rates for adult onset MCD (complete or partial 81% to 91%, complete 72.5% to 77.3%) [27, 28] and idiopathic FSGS with nephrotic syndrome (complete or partial, 50% to 65.7%, complete remission, 20% to 41%) [22, 23, 29, 30] . The low incidence of documented relapse in our series (2/29 patients) may reflect the relatively short follow-up (median 13 months, range 3 to 96 months). By comparison, a recent study reported relapse of nephrotic syndrome in 33% of adult MCD patients, with a median time to relapse of 30 months [31] . ESRD is a rare occurrence in GTL, affecting only one of 29 patients in the present study. This extremely low incidence is comparable to previously reported incidences of ESRD in MCD; Nolasco et al [27] reported death from uremia in only one of 89 adults with MCD, whereas Korbet, Schwartz, and Lewis [28] described progression to ESRD in two of 40 adult patients with MCD. By contrast, the reported incidence of ESRD in idiopathic FSGS with nephrotic syndrome is 50% over 5 to 10 years [19] . Thus, outcome in GTL appears better than that of idiopathic FSGS with respect to both achievement of complete remission and renal functional preservation, at least within the relatively short period of follow-up in this study. Among the eight GTL patients who had renal insufficiency at presentation and for whom follow-up data were available, five subsequently had stable renal function, and three had normal renal function. These findings support a role for heavy proteinuria precipitating reversible acute tubular injury in some GTL patients, as reported for patients with MCD [17] .
These similarities to MCD and FSGS raise questions about how GTL should be classified within the MCD/FSGS spectrum. Is GTL a nonspecific morphologic feature seen in some patients with MCD or should it be considered a morphologic variant of FSGS? Our data support that GTL occupies an intermediate position within the clinical-pathologic spectrum of MCD/FSFS and there is some validity to both approaches. From a practical diagnostic standpoint, GTL may be considered a highly favorable prognostic subcategory within the broader clinical-pathologic continuum of MCD/FSGS. Although the presence of perihilar sclerosis was not an exclusion criterion for diagnosis of GTL in this study, the absence of this finding in all initial GTL biopsies validates the recognition of GTL as a phenotypically distinct variant whose segmental lesions are paratubular and predominantly cellular in character. The favorable outcome with respect to steroid responsivity and extremely low incidence of progression to ESRD indicate that this distinction is clinically relevant. Future studies of outcome in idiopathic nephrotic syndrome should control for patients with this favorable morphologic variant. Additional studies are needed to determine the morphogenesis and potential reversibility of this lesion.
